In another study, in the process of pancreatic carcinogenesis, intratumoral SETD2 deficiency not only participated in the regulation of pancreatic tumor cell fate, but also regulated immune escape by remodeling neutrophils, which may provide potential therapeutic targets for pancreatic cancer patients with SETD2 mutation or loss (Niu et al., 2023). The gene discussed is SETD2; the disease is pancreatic neoplasm.